Phase I/II Trial of Dasatinib (Sprycel) With Radiation Therapy and Concomitant and Adjuvant Temozolomide in Patients With Newly-Diagnosed Glioblastoma.
Phase of Trial: Phase I
Latest Information Update: 01 Feb 2016
At a glance
- Drugs Dasatinib (Primary) ; Temozolomide
- Indications Glioblastoma; Gliosarcoma
- Focus Adverse reactions
- 10 Sep 2013 Status changed from active, no longer recruiting to discontinued as reported by M.D. Anderson Cancer Center.
- 26 Feb 2013 Planned End Date changed from 1 May 2013 to 1 May 2014 as reported by ClinicalTrials.gov.
- 01 Nov 2011 Planned end date changed from 1 May 2012 to 1 May 2013.